Delphi Advised IRLAB Therapeutics AB (publ) in Connection with IPO of SEK 115 Million and Listing on Nasdaq First North Premier
March, 2017 - Göteborg, Sweden
Delphi acted as advisor to IRLAB in connection with an IPO of approx. SEK 115 million as well as its listing on Nasdaq First North Premier. The first day of trading was 28 February 2017.
IRLAB is a drug discovery and development company providing novel treatment for disorders of the brain, with focus on Parkinsons disease and dementia. IRLAB has two drug candidates, IRL752 and IRL790, for which clinical phase 1 studies have been completed, three projects in pre-clinical phase as well as a research program that aims at identifying further drug candidates.
Delphi’s team consisted of inter alia Dag Fredlund (responsible partner), Annika Bergman, Hanne Kirnö and Kristina Lemke.
